HBV-IN-45

Cat. No.:	HY-163516
Molecular Formula:	$C_{16}H_{16}N_2O_2S$
Molecular Weight:	300.38
Target:	HBV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HBV-IN-45 is a selective and orally active HBV capsid assembly modulator with an IC_{50} of 0.51 μM for HBcAg in HBC cells. HBV-IN-45 shows potent anti-HBV activities[1].
In Vitro	HBV-IN-45 (compound 26f) inhibits the growth of HepG2 cells with a $CC5_{50}$ values of 84.29 μM. HBV-IN-45 also inhibits HBV DNA in HepAD38 cell supernatant with an EC_{50} of 2.24 μM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	HBV-IN-45 (compound 26f; 100 mg/kg; oral administration; twice daily; for 14 days) inhibits HBV DNA copy numbers in plasma, and the HBeAg and liver enzymes GPT (ALT) in mouse serum have no difference[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/c mice injected with replication-competent HBV 1.3 DNA plasmid[1]
Dosage:	100 mg/kg
Administration:	Oral administration; twice daily; for 14 days
Result:	HBV DNA copy numbers were rapidly and markedly reduced in plasma.

REFERENCES

[1]. Kaixin Du, et al. Development of benzimidazole-based compounds as novel capsid assembly modulators for the treatment of HBV infection. Eur J Med Chem. 2024 Apr 16:271:116402.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA